Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesNyrada Inc

Nyrada Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.495 AUD 0.05 ( 11.24%)
Last update at 2026-11-06T05:10:00Z
VOLUME
268415
Market Cap
128.63M

Momentum Score

…

Nyrada Inc., a clinical-stage biotechnology company, focuses on the discovery and development of small-molecule therapies for neuroprotection and cardioprotection indications in Australasia. Its lead candidate is Xolatryp, a small-molecule inhibitor targeting the transient receptor potential canonical ion channel subtypes 3, 6, and 7, which is in a Phase IIa clinical trial to treat myocardial ischemia, arrhythmia, stroke, and traumatic brain injury, as well as in a preclinical research stage for oncology indications. Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.45
Low
0.49
High
52 Week Price Range
0.39
Low
1.44
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Nyrada Inc is an Australian clinical-stage biotechnology company developing small-molecule therapeutics for cardiovascular and neurological disorders. Its long-term growth may be driven by successful progression of development programs, favourable clinical outcomes and potential licensing or commercialization deals addressing significant unmet medical needs. Investors may find the company attractive for milestone-driven upside tied to pipeline advancement in large therapeutic areas.

Principal investment risks include high clinical and regulatory risk, the likely need for additional funding with potential equity dilution, limited revenue history and intense competition in cardiovascular and neurological therapeutics.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.45
Dividend Yield
-
Revenue TTM
2.01M
Revenue Per Share
0.01
Gross Profit TTM
-1.20M
Debt / Equity
-
ROE
-99.95%
Net Debt
-8.38M
ROCE
-89.76%
Diluted EPS TTM
-0.03

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -8.53M -4.85M -4.60M -7.78M -3.96M
Net income -6.53M -4.85M -1.39M -7.78M -3.96M
Selling general administrative 5.06M 1.44M 1.06M 2.28M 2.67M
Selling and marketing expenses - 1.40M 1.49M - -
Gross profit -0.00M -1.98M -0.81M - -
Reconciled depreciation 0.00M 0.00M 0.01M 0.01M 0.00M
Ebit -8.57M -5.01M -4.60M -9.36M -3.96M
Ebitda -8.57M -5.00M -4.60M -9.35M -3.95M
Depreciation and amortization 0.00M 0.00M 0.01M 0.01M 0.00M
Operating income -8.57M -9.20M -4.56M -9.36M -3.96M
Other operating expenses 8.57M 11.60M 6.60M 9.36M 5.07M
Interest expense - - - - 0.00M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.18M 0.16M 0.16M 0.15M 0.01M
Net interest income 0.18M 0.16M 0.16M 0.15M 0.01M
Income tax expense -2.00M -2.40M -3.22M -0.15M 0.00M
Total revenue - 2.40M 3.24M 1.58M 1.11M
Total operating expenses 8.57M 7.22M 4.56M 9.36M 5.07M
Cost of revenue 0.00M 4.38M 2.03M - -
Total other income expense net 0.04M 4.36M -0.04M 1.43M -0.00M
Net income from continuing ops -6.56M -4.85M -1.39M -7.78M -3.96M
Net income applicable to common shares - -4.85M -1.39M -7.78M -3.96M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 10.42M 5.30M 5.91M 5.16M 12.01M
Intangible assets 0.03M 0.03M - 0.03M 0.04M
Other current assets 0.20M - 0.08M - 0.08M
Total liab 0.88M 1.72M 0.86M 0.91M 0.52M
Total stockholder equity 9.54M 3.58M 5.05M 4.26M 11.50M
Other current liab 0.68M - 0.72M 0.38M 0.41M
Common stock 40.03M - 26.84M 25.32M 25.32M
Capital stock 40.03M 29.77M - 25.32M 25.32M
Retained earnings -35.29M -29.58M -27.19M -27.22M -19.52M
Other liab - - - 0.02M 0.04M
Cash 8.38M 2.93M 4.77M 3.71M 10.82M
Cash and equivalents - - - - 10.82M
Total current liabilities 0.87M 1.72M 0.84M 0.88M 0.47M
Net debt -8.38M - -4.77M -3.71M -10.82M
Short term debt - - - - 0.00M
Other stockholder equity - - - 6.15M 5.69M
Property plant equipment - - - 0.00M 0.01M
Total current assets 10.38M 5.27M 5.87M 5.13M 11.97M
Net tangible assets - - - 4.22M 11.46M
Net receivables 1.80M 2.16M 1.02M 1.42M 1.07M
Accounts payable 0.19M 0.91M 0.12M 0.51M 0.07M
Accumulated other comprehensive income 4.80M - 5.40M 6.15M 5.69M
Non currrent assets other - - 0.03M - -
Non current assets total 0.04M 0.03M 0.03M 0.04M 0.04M
Long term debt total - - - - 0.00M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - 0.00M 0.00M - -0.00M
Change to liabilities - - - 0.25M -0.20M
Total cashflows from investing activities -0.01M 0.00M 0.00M 0.00M -0.00M
Total cash from financing activities 9.96M 3.19M 1.83M 0.00M -0.27M
Change to operating activities - - - 0.05M 0.06M
Net income -6.53M -4.85M -1.39M -7.78M -3.96M
Change in cash 5.45M -1.84M 1.06M -7.11M -2.93M
Begin period cash flow 2.93M 4.77M 3.71M 10.82M 13.75M
End period cash flow 8.38M 2.93M 4.77M 3.71M 10.82M
Total cash from operating activities -4.49M -5.05M -0.77M -7.20M -3.96M
Issuance of capital stock 10.41M 3.45M 1.97M - -
Depreciation 0.00M 0.00M 0.01M 0.01M 0.00M
Other cashflows from investing activities - 0.00M 0.00M - -
Change to account receivables 0.34M -1.24M 0.31M -0.26M 0.21M
Sale purchase of stock -0.41M -0.25M -0.14M - -0.22M
Other cashflows from financing activities - 3.19M 0.01M 0.00M -0.04M
Change to netincome - - - 0.54M 0.97M
Capital expenditures 0.01M 0.00M 0.00M 0.00M 0.00M
Change in working capital -0.48M -1.19M 0.26M 1.32M 1.37M
Stock based compensation - 0.18M - - -
Other non cash items 2.51M 0.80M 0.36M - 3.96M
Free cash flow -4.50M -5.05M -0.77M -7.20M -3.96M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
NYR
Nyrada Inc		 0.05
11.24%		 0.49 - - 63.95 13.21 -2.17
CSL
CSL Ltd		 -0.36
0.18%		 202.04 - 22.57 6.15 4.48 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.41
2.91%		 13.67 93.87 166.67 5.37 6.37 47.29
NEU
Neuren Pharmaceuticals Ltd		 -
-%		 23.24 154.93 36.36 42.38 7.52 160.40
MSB
Mesoblast Ltd		 -0.14
6.45%		 2.03 - 454.55 23.43 3.36 -9.86

Profile*

Nyrada Inc

Nyrada Inc., a clinical-stage biotechnology company, focuses on the discovery and development of small-molecule therapies for neuroprotection and cardioprotection indications in Australasia. Its lead candidate is Xolatryp, a small-molecule inhibitor targeting the transient receptor potential canonical ion channel subtypes 3, 6, and 7, which is in a Phase IIa clinical trial to treat myocardial ischemia, arrhythmia, stroke, and traumatic brain injury, as well as in a preclinical research stage for oncology indications. Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.

Salesforce Tower, Sydney Place, Sydney, NSW, Australia, 2000

61 2 9498 3390

https://www.nyrada.com

Name Title Year Born
Mr. James Bonnar Chief Exec. Officer NA
Mr. Cameron Jones C.A. Chief Financial Officer NA
Mr. Benjamin Evison Ph.D. Chief Scientific Officer NA
Ms. Laura Vize Investor Relations Mang. NA
Mr. Mark Waring B.Sc., P.M.P. Sr. VP of US Operations NA
Mr. David James Franks B.Ec, BEc, C.A., CA, F Fin, J.P., JP. Company Sec. 1970
Mr. James Bonnar Chief Executive Officer NA
Mr. Dimitri Burshtein Investor Relations Manager NA
Mr. Mark Waring B.Sc., P.M.P. Senior Vice President of US Operations NA
Mr. David James Franks BEc, C.A., F Fin, J.P. Company Secretary 1970

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…